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Abstract
The assessment of dose-response is an integral component of the drug development
process. Parallel dose-response studies are conducted, customarily, in preclinical and
phase 1, 2 clinical trials for this purpose. Practical constraints on dose range, dose levels
and dose proportions are intrinsic issues in the design of dose response studies because of
drug toxicity, ecacy, FDA regulations, protocol requirements, clinical trial logistics, and
marketing issues. We provide a free on-line software package called Controlled Optimal
Design 2.0 for generating controlled optimal designs that can incorporate prior informa-
tion and multiple objectives, and meet multiple practical constraints at the same time.
Researchers can either run the web-based design program or download its stand-alone
version to construct the desired multiple-objective controlled Bayesian optimal designs.
Because researchers often adopt ad-hoc design schemes such as the equal allocation rules
without knowing how ecient such designs would be for the design problem, the program
also evaluates the eciency of user-supplied designs.
Keywords: Bayesian optimal design, dose response study, logit model.
1. Introduction
The logit model is popular for describing the underlying dose response relationships in dose
response studies (Abdelbasit and Plackett 1983; Chaloner and Larntz 1988, 1989; Kalish 1990;
Carr and Portier 1993; Smith and Ridout 1998; Zhu et al. 1998; Zeng et al. 2000; Zhu and Wong
2001; Baek et al. 2006). Chaloner and Larntz (1989) provided a Fortran program, called Logit
Design 1.0, for computing Bayesian single-objective optimal designs for the logit model, which2 Controlled Optimal Design Program for the Logit Dose Response Model
has attracted attention in the optimal design community. Later, the program was generalized
in Zhu (1996) to accommodate the commonly encountered multiple-objectives scenarios in
dose response studies. This Generalized Multi-Objective Logit Design program was applied
to several dose response studies (Ahn et al. 1998; Zhu et al. 1998; Zeng et al. 2000; Zhu and
Wong 2000a, 2001; Mugno et al. 2004). However, this program has drawbacks because it
cannot incorporate specic constraints on the dose range, dose levels, and dose proportions
for a give study, which frequently arise in practice; see for example, Kaine et al. (1995), Zeng
and Zhu (1997), Mason et al. (2002), Shahinfar et al. (2005), and Cohen et al. (2007). In
recent years, some progress has been made in incorporating more information and realistic
constraints into the design framework. For example, Scazzero and Ord (1993) restricted the
range of dose response probabilities in an industrial experiment, Mats et al. (1998) showed
that unusual design space can arise naturally in the design of phase 1 cancer clinical trials,
and Imhof et al. (2002, 2004) and Baek et al. (2006) proposed to incorporate information of
potential missing observations at the design stage. However, to our best knowledge, there is
no free software program that allows multiple objectives and constraints to be accounted for
at the design stage.
In this paper, we proposed an optimal design software called the Controlled Optimal Design
2.0 that integrates a modern class of optimization algorithms into a single package for practi-
tioners in the health sciences. These optimization algorithms include both global optimizers
such as the cross entropy (CE) method (Rubinstein and Kroese 2004) and local search proce-
dures such as stochastic gradient search (Spall 1992), which are popular and standard tools
for solving practical problems in the operations research community. We believe that this is
the rst time such techniques are applied to the optimal design literature. Our program han-
dles dierent practical constraints, multiple objectives, prior information, and formulates the
underlying design problem as a constrained non-linear optimization problem. The resulting
optimization problem is then solved using the aforementioned built-in optimizers, leading to
a feasible design we call the \controlled optimal design". We have successfully applied this
program to re-design several dose response studies. Our preliminary study indicates that the
resulting controlled optimal designs can signicantly outperform the designs actually imple-
mented in the studies. The program is freely available to the public in two formats: (1) a
web-based version from http://www.optimal-design.org/; (2) a stand-alone version that
can be downloaded from the same website. It is our hope that the optimal design website
will serve as a modern forum for information exchange between the users and developers of
the Controlled Optimal Design 2.0 program. Our research is still on-going, and we plan to
expand the functionality of the current design software to accommodate other dose response
models, design objectives, and constraints. A newer website with additional capabilities is
available at http://optimal-design.biostat.ucla.edu/optimal/.
2. Logit model and optimal design terminologies
The logit dose response model
ln
(x)
1   (x)
= (x   )
links the dose level x to the probability (x) of observing a response (e.g., drug is eective)
at the given dose. The parameter  is the slope in the logit scale. The parameter 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median in the logit scale and is commonly referred to as the \median eective dose". This
parameter is sometimes denoted by ED50, where ED stands for eective dose. More generally,
let ED100 be the dose level corresponding to a response probability . It follows that
ED100 = x =  +
1


ln

1   

:
A typical research goal is to estimate one or more dose levels ED100i as accurately as possible
for user-selected i's. Another goal is to estimate the underlying dose response curve (i.e. the
logit model parameters) as accurately as possible. One of our main aims in this paper is to
nd an optimal design for estimating one or more of these parameters.
Any design  can be represented in the form
 =
(
x1 x2  xk
p1 p2  pk
)
;
where k is the number of dose levels and pi is the proportion of subjects assigned to the dose
level xi. In this work, we follow the approximate optimal design approach (Kiefer 1974; Silvey
1980; Pukelsheim 1993). In particular, given an optimality criterion, our design problem is
to nd the optimal value of k, the dose levels xi, and the proportion of subjects assigned to
each of these dose levels, pi i = 1;2;:::;k. In practice, the total number of available subjects
N is predetermined either by cost or time considerations, and our optimal design  assigns
roughly Npi (rounded to the nearest integer) subjects to the dose level xi, subject to the
constraint that
Pk
i pi = 1. Over the years, Kiefer's approach has proven to be practically
useful. In particular, algorithms are available for nding a variety of optimal designs and
analytical solutions become possible in many cases.
Let > = (;); t =
P
pjwj;  x = t 1 P
pjwjxj; s =
P
pjwj(xj    x)2, and wj = (xj)[1  
(xj)]. For the logit model, Zhu and Wong (2001) showed that the normalized observed
Fisher information matrix for the design  is
M(;) =
 
2t  t( x   )
 t( x   ) s + t( x   )2
!
:
To estimate a given function of the model parameter c(), one can use the Bayesian C-
optimality criterion to minimize the estimated asymptotic variance of c(), i.e.,
() = E
h
rc()
i>
M 1(;)
h
rc()
i
;
where the expectation is taken with respect to the prior distribution of . Another important
criterion is the Bayesian D-optimality criterion that estimates the logit dose response curve by
minimizing the estimated volume of the joint condence ellipsoid of the two model parameters
() = E
 
M 1(;)
 
:
Both types of Bayesian single-objective optimality criteria were used in Chaloner and Larntz
(1989). Bayesian optimal designs clearly generalize locally optimal design proposed by Cher-
no (1953), because the latter designs assume a degenerate prior distribution. Both these
two types of optimality criteria are convex functions of the information matrix and so results4 Controlled Optimal Design Program for the Logit Dose Response Model
from convex analysis can be applied to justify the optimality of the design (Silvey 1980). To
evaluate the performance of an arbitrary design relative to an optimal design , we measure
its design eciency by
e() = ()=():
To accommodate multiple design objectives such as the estimation of certain percentiles of
interest and/or the estimation of the individual parameters in the dose response curve, one
may formulate the design problem as a constrained problem as follows. First, prioritize the
importance of each objective; if there are m objectives, the user species the desired eciency
of the design for each criterion; naturally we want the design to have higher eciencies for
more important criteria or objectives. Subject to these user-specied eciency requirements
for all objectives, except for the least important criterion, the optimization problem is to
maximize the design eciency of the least important criterion within the class of designs
already guaranteed to meet all other eciency requirements. Although this formulation is
both appealing and intuitive, it does not provide a clue how to determine the optimal design.
An alternative and more practical approach is to work with the compound optimality crite-
rion proposed in Cook and Wong (1994). This approach incorporates multiple objectives into
a single criterion by using a convex combination of all the objectives. Because each crite-
rion is convex, the new criterion is also convex. Thus for each convex combination, standard
algorithm can be used to generate an optimal design for the new criterion. The resulting
compound optimal design is found by minimizing the new criterion, and has a nice interpre-
tation for a given choice of the weights employed in the convex combination. Specically, they
relate to the eciency requirements in the formulation of the constrained design problem; in
particular, the sought constrained optimal design is one of the compound optimal designs and
the next problem is to make the identication. Cook and Wong (1994), Clyde and Chaloner
(1996), Zhu and Wong (2000a, 2001) provided details and illustrations.
As a brief illustration, suppose the individual design objective functions are i, i = 1;:::;m
and each is a convex function of the information matrix. The (non-standardized) compound
optimality criterion is
(j) =
m X
i=1
ii();
where 0  i  1,
P
i = 1 are user selected weights. For the given set of weights, the design
that minimizes this criterion is called a compound optimal design. When the magnitude
of the individual design objective functions varies substantially, the standardized compound
optimality criterion proposed by Dette et al. (2005) is preferred:
(j) =
m X
i=1
i
h
i()=i(
i )
i
;
where 
i is the optimal design for objective i, i = 1;:::;m and the ratio represents the
eciency of the design  relative to the optimal design for the ith objective. In practice,
for each set of weights, a compound optimal design is determined. The desired constrained
optimal design is then found from within the class of compound optimal designs. When there
are two objectives, the desired constrained optimal design can be determined graphically
from the class of compound optimal designs using an eciency plot; see e.g., Cook and Wong
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3. Controlled optimal design
The traditional Bayesian multiple-objective optimal designs (Chaloner and Larntz 1988, 1989;
Zhu 1996; Zhu and Wong 2000a, 2001) impose no constraint on the underlying dose range,
dose levels, and dose proportions. Furthermore, they do not incorporate information on
potential missing observations at dierent dose levels nor do they allow specic dose levels to
be automatically included in the design. These drawbacks can be serious limitations for the
pharmaceutical industry. For example, FDA (Food and Drug Administration) guidelines to
the industry stipulate that on dose response studies, a positive dose response relationship can
be demonstrated either through a positive slope or through a signicantly higher proportion
of responders at an active dose level in comparison to the placebo. Therefore, many parallel
dose-response studies require the placebo (dose 0) to be included as one of the dose levels.
However, one cannot force the placebo (or any other xed dose level) to be a selected dose
level in the traditional optimal design framework.
The controlled optimal design concept was developed over the last decade with collaborative
work from colleagues in the pharmaceutical industry. The program removes several of the
above limitations and provides added exibility. In the current version of the Controlled
Optimal Design 2.0 program, we have implemented features to accommodate constraints on
the following design parameters:
1. Restricted design interval. The traditional optimal design assumes the underlying
dose range to be ( 1;1). This may result in an optimal design with the lower dose less
than the placebo and/or with the upper dose level higher than the safety limit. The user
can now dene their own dose range based on their ecacy and toxicity considerations.
2. Dose levels. The user can include certain dose levels of interest such as the placebo
and/or dose levels being considered for the drug label (and thus direct observation of the
response rates at such dose levels would be desirable) as xed optimal design support
points. The user can also specify a range for each dose level to be used. For example, in
some studies, it is desirable to include a lower dose, a medium dose, and a higher dose.
3. Dose proportions. For each dose level, the user dene the range of its corresponding
allocation proportion. In a 4-dose study, for example, we may require that at least
15% or no more than 35% of subjects are allocated at some dose levels because of trial
logistics or the expected higher dropout rates at certain dose levels.
4. Potential missing observations. Sometimes a dose response study has lots of missing
observations near the end of the trial due to subject drop-out. The reasons for drop-out
typically include lack of eciency and/or the presence of drug toxicity or simply fatigue
over time especially if we have a trial that goes on for years. To capture information
for the distribution of missing data at dierent dose levels at the design stage, we
provide three potential non-missing probability functions in our package. Let (x) be
the percentage of subjects at dose level x that are expected to complete the study. The
three available forms are the logit, exponential, and symmetric non-missing probability
functions given by (x) = [1 + exp(ax   b)]
 1, (x) = 1   aexp(bx   c), and (x) =
a(b   x)2 + c, respectively. Here a, b, and c are user selected constants that can be
estimated from a pilot/previous study. Details for this methodology are given in Imhof
et al. (2002, 2004) and Baek et al. (2006).6 Controlled Optimal Design Program for the Logit Dose Response Model
3.1. The optimization algorithms
We now provide a brief description of the main ideas in the Controlled Optimal Design 2.0
program. The package consists of a global search component and a local search component.
The idea is to use the global search to escape from local optima and locate promising regions
of the solution space containing high quality solutions. We then use the local search to ne-
tune the solutions obtained from the global search phase. Since the optimal design problem
is highly constrained, multi-dimensional, and nonlinear with possibly many locally optimal
solutions, a random sampling-based approach is used in our Controlled Optimal Design 2.0
program. Compared to traditional optimization approaches such as the simplex method and
the gradient-based method, our approach is more robust and is not sensitive to initial starting
values/guesses.
Specically, the global search component in our program is based on the recently proposed
cross-entropy (CE) method (Rubinstein and Kroese 2004) in the operations research commu-
nity. The CE method is an iterative approach that is based on random sampling from an
underlying probability distribution model on the solution space, which is updated iteratively
after evaluating the performance of the samples at each iteration. The essence of the method
is to gradually concentrate the distribution model on promising regions of the solution space
so that the probability of generating/sampling high quality solutions increases as the sampling
process proceeds.
One diculty in applying CE to the controlled design problem is how to eciently generate
feasible designs (candidate solutions) from the restricted design space. Note that the design
space is characterized by the following two types of constraints: (i) the set of constraints
gi()  0, i = 1;:::;m that form hyper-rectangles (e.g., restrictions on dose intervals, dose
levels, and dose proportions), and (ii) the set of constraints hj()  0, j = 1;:::;n that
form multi-dimensional simplexes (for example, the set of dose proportions need to satisfy
the constraints
Pk
i=1 pi = 1, pi  0). In the actual implementation of the Controlled Optimal
Design 2.0 program, an acceptance-rejection (AR) approach is used to handle the rst type of
constraints. The AR approach starts by generating feasible designs from the unconstrained
design space, and then either accepts or rejects the generated designs by checking whether or
not they fall in the regions dened by the constraints. For constraints of type (ii), a penalty
function approach is used to include the constraints as parts of an unconstrained optimization
problem. The optimization problem is now formulated as the weighted combination of the
original objective function and a function that penalizes violation of constraints of type (ii),
^ (j) = (j) +
n X
j=1
cj maxfhj();0g;
where cj > 0 is the cost incurred by violating the jth constraint hj()  0.
Once a good design is found in the global search phase, it can be used as an initial solution
in a local search method to nd further improved designs. To ensure high quality solutions,
the local search component of our program consists of two phases   a pure local search
phase followed by a gradient-based search. A high level description of the pure local search
method is as follows. Specically, let t be the current best design found at the tth iteration
of the algorithm. We start by randomly (uniformly) generating N new designs from the
neighborhood of t. If a new design is found to be better than t, it replaces t as the new
current best design. The above steps are performed iteratively until no further improvementJournal of Statistical Software 7
is obtained for several consecutive iterations. At the second phase, the gradient-based search
takes the general recursive form
t+1 = 

t   at^ Lt(t)

;
where ^ Lt(t) represents an estimate of the performance gradient at the current design t , at
is the step size, and  denotes a projection on the feasible design space characterized by the
constraints. The gradient estimation can be carried out via a number of dierent techniques.
Here we have used a two-sided simultaneous perturbation approximation approach (Spall
1992), where all elements of t are randomly perturbed to obtain two measurements of (j),
and the jth directional gradient is estimated by
^ Li;j =
(t + tctj)   (t   tctj)
2ctt;j
;
where t = (t;1;:::;t;2k)> is a random perturbation vector and fctg is a sequence of con-
stants that gets smaller as the number of iterations t increases. For detailed implementation
issues of how to choose the perturbation vector and the sequence fctg, we refer the reader to
Spall (1992).
3.2. Controlled optimal design program 2.0, the stand-alone version
The original Controlled Optimal Design 2.0 is written in MATLAB (The MathWorks, Inc.
2007). An executable stand-alone version of this program is provided on the optimal design
website. For greater time eciency, the user should download this program and run it on
their own computers. The rst-level menu of the stand-alone program is as follows:
Options:
(1) specify the number of dose levels
(2) calculate the optimal number of dose levels
(0) quit the program
Once the user selects option (1) or (2), the second-level menu appears as follows.
Options:
(1) specify the dose range
(2) specify dose levels (e.g., placebo)
(3) specify dose proportions
(4) specify an initial design (optional)
(5) specify the initial prior
(6) select the optimality criterion
(7) select the design criterion
(8) specify information on potential missing observations
(9) specify the number of iterations
(10) calculate the optimal design
(11) evaluate the criterion value for the current design
(12) print out the current values
(0) quit the program8 Controlled Optimal Design Program for the Logit Dose Response Model
To compute a controlled-optimal design, the user should choose options (1) through (10)
in turn. Most of these options are self-explanatory except options (6) and (7). For option
(6), the user chooses whether to use the non-standardized or the standardized compound
optimal design criterion. We also provide the user with two approaches to estimate the model
parameters. In Approach 1, we estimate each model parameter using the C-optimal design
criterion and subsequently add these and other C-optimal design criteria for user-selected
percentiles of interest under a unied compound C-optimal design. In Approach 2, we estimate
both model parameters jointly using the D-optimal design criterion and subsequently adding
this and other C-optimal design criteria for selected percentiles of interest under a unied
compound C- and D-optimal design. Therefore we have 4 choices in option (6) as follows.
Available options:
(1) standardized compound C-optimal design
(2) standardized compound C- and D-optimal design
(3) non-standardized compound C-optimal design
(4) non-standardized compound C- and D-optimal design
(5) go back to main menu
After selecting the desired approach in option (6), the user proceeds to option (7) to specify
the individual objectives (percentiles etc.) and the corresponding weights (i's) for the chosen
compound optimal design criterion. The user can print out the current values for options (1)
through (9) by choosing option (12). Additionally, the user can also evaluate the design
criterion value for an arbitrary design (for example, the equal allocation rule) by entering this
design through option (4) and evaluating its value under the current design layout via option
(11).
3.3. Controlled optimal design program 2.0, the web-based version
The Controlled Optimal Design 2.0 program is available at the following website http://www.
optimal-design.org/optimal/polynomial/ControlledDesign.aspx. A detailed introduc-
tion precedes the program and we have tried to make every option self-explanatory. For each
option, every value entered by the user is stored in the memory and ready to be selected from
the pull-down menu directly the next time around. The user will nd the web-based program
more user friendly than the stand-alone version. However, to allow greater access to other
users and release computing burden on our server, the web-based program will automatically
terminate a program if the running time exceeds 5 minutes. As an alternative, we provide the
user with the exibility of having a stand-alone program to run the same program on their
own computers. Screen shots of portions of the web-based program are shown in Figures 1
and 2.
The web-based Controlled Optimal Design 2.0 program adopts the client/server mode. The
application consists of a web interface and a web-based MATLAB program to perform the cal-
culation. Whenever a user submits a request through the web page, the web-based MATLAB
program is invoked to run on the server end. The parameters specied on the web page are
passed to the MATLAB program in the form of an HTTP request. When the calculation is
complete, the results are sent back to the web page for display.
The application is developed on Windows XP and on the Microsoft Internet Information
Services (IIS) web server. The web interface is essentially a web application developed usingJournal of Statistical Software 9
Figure 1: An introduction to the web-based Controlled Optimal Design 2.0 program.
ASP.NET with C# (Microsoft Corporation 2003). The web-based MATLAB program is a
modied version of the stand-alone program discussed above, with the input/output part
adapted to the MATLAB web server format. The MATLAB web server is a MathWorks
product that connects the web application to the web-based MATLAB program, passing data
back and forth between the two.
The web interface encompasses a web page and C# code. The web page enables the user to
specify the constraints and parameters for the controlled optimal design. Upon submission
of the user input, the C# code is invoked to validate the input, combine it into a MATLAB
structure, and then transform it into a byte array. An HTTP request is created thereafter by
an ASP.NET built-in class: HttpWebRequest. The byte array is sent, via the HTTP request,
to the MATLAB web server.
The MATLAB web server depends upon the TCP/IP networking for transmission of data
between the web browser and MATLAB. It collects the input MATLAB structure from the
HTTP request and passes it to an m-le (the MATLAB code le) specied in the input
structure. The m-le obtains input values from the MATLAB structure and assigns them
to the variables of interest. The MATLAB program then performs the computation and
generates the optimal design results. Finally, the program combines the output values into a10 Controlled Optimal Design Program for the Logit Dose Response Model
Figure 2: The input screen of the web-based Controlled Optimal Design 2.0 program.
MATLAB output structure, and calls the function htmlrep to place the output structure into
an HTML output document template, which is an HTML le containing the names of the
output variables. The MATLAB web server then sends the data back to the web application
in the form of an HTTP response. Subsequently, the C# code behind the web page receives
the HTTP response via the C# built-in class httpWebResponse. The data passed back by
the MATLAB web server are stored into a C# string. Values of the variables are obtained
from the resulting string and displayed onto the web page. More technical details on the
ASP.NET web application, the MATLAB web server, and web-based MATLAB programming
can be found on http://www.microsoft.com/ and http://www.mathworks.com/.
4. An example
We now demonstrate how to use the Controlled Optimal Design 2.0 program to re-design
a placebo controlled dose-nding study for greater eciency. Various daily dosage of the
drug Tacrolimus shown in Table 1 was used to treat rheumatoid arthritis (RA) patients for
24 weeks (Kondo et al. 2004). Prior to this trial in Japan, a dose-ranging trial on the same
drug was conducted in the United States (US), Furst et al. (2002), and information from thisJournal of Statistical Software 11
Dose levels (in mg) 0 1 3 5 Total
Number of subjects allocated to the dose level 71 69 64 64 268
Number of subjects completed the study 29 40 34 38 141
Number of subjects with improvement at the given dosage 11 20 22 32 85
Table 1: Summary of a dose ranging study on Tacrolimus reported by Furst et al. (2002).
trial was used in the dose response model for the Japanese study. In the US trial, 268 patients
with RA who were resistant to or intolerant of methotrexate (mean dose 15.2mg/week) and
had active disease for at least 6 months (mean tender joint count 28.2, mean erythrocyte
sedimentation rate 46.5mm/hour) were randomized to receive treatment after discontinuation
of methotrexate. Patients are judged to have benetted from the treatment if the patient
showed at least a 20% improvement in several measures. The key outcome is a composite
binary outcome commonly called the ACR20. This binary outcome is a validated measure
from the American College of Rheumatology and takes on the value 1 if the patient had
improved and 0 otherwise. Data from the US study is summarized in Table 1.
The US study found the 5mg dose to be overly toxic and so the Japanese study was re-
stricted to the dose interval (1mg;3mg]. We used the SAS PROC NLMIXED procedure (SAS
Institute Inc. 2008b) and determined the dose response relationship between subjects who
completed the study and subjects who showed improvement in the study (rows 2 and 3 in
Table 1). The tted model was the logit model with estimated parameters ^  = 1:166 and
^  = 0:410 with corresponding standard errors 0.495 and 0.103, respectively. We constructed
the prior distributions for  and  in the Japanese study using the 95% condence inter-
vals for the two parameters. The resulting prior distributions were   U[0:188;2:143] and
  U[0:206;0:615]. In Controlled Optimal Design 2.0, we provide more exibility for the
user to select the prior distributions. The user can select any independent beta distributions
on any arbitrary intervals as their prior distributions for the two logit model parameters. This
includes the uniform distribution as a special case when both beta distribution parameters
are set to 1.
The data in Table 1 shows there are missing data in the trial. Our program can make
use of this information to design an improved trial. We do this by estimating the form
and parameters in the potential non-missing probability function discussed in Baek et al.
(2006) and Imhof et al. (2002, 2004). This function estimates the probability of having an
observation at dose x. In practice, it is a monotonically increasing function since we expect
more dropouts as the dose levels are increased due to toxicity eects. Our analysis used
subjects who entered the study and subjects who completed the study (rows 1 and 2 in
Table 1). We used the SAS PROC LOGISTIC (SAS Institute Inc. 2008a) procedure and the
MATLAB FIT function to determine that the best tted potential non-missing probability
function is ^ (x) = 1   exp( 0:053x   0:643). The observed percent of patients completing
the trial at the 4 doses were respectively given by 41%, 58%, 53%, and 59% versus the tted
percentages of 47%, 50%, 55%, and 60%. Our program provides three types of potential
missing probability functions that we feel are likely to arise in practice. For this particular
example, the exponential non-missing probability function appears to be the best model to
t the data at hand.
Now we are ready to construct the Bayesian multiple-objective controlled optimal design for12 Controlled Optimal Design Program for the Logit Dose Response Model
the Japanese study on Tacrolimus (Kondo et al. 2004). In dose response studies, the major
objectives are usually the estimation of the underlying dose response curve and the estimation
of key dose levels such as the threshold dose. The threshold dose is often dened as the dose
that is more eective than the placebo by a certain percentage (Zeng and Zhu 1997). For the
given study, we infer that the threshold dose is dened as the dose level that is 15% more
ecient than the placebo. Since 11 out of the 29 patients allocated to the placebo completed
the 6-month trial in the US study (Table 1), the success rate of the placebo is estimated to be
11=29  0:38. Thus the placebo is estimated as ED38, and the threshold dose is estimated as
ED53. We also learned that the Japanese study was designed as a 3-dose trial that required
0 and 3mg doses, with the third dose in a medium dose range somewhere between 1mg to
2mg. For better clinical trial logistics and potential missing trial considerations, it was also
desired that each dose level has at least 25% of the subjects in the study.
The constraints and prior information for the Kondo et al. (2004) trial are summarized as
follows:
1. Number of dosages: 3.
2. Dose range: [0;3mg].
3. Dose levels:
(a) Dose 1: placebo.
(b) Dose 2: in the interval of [1mg;2mg].
(c) Dose 3: 3mg.
4. Dose proportions:  25% at each dose level.
5. Priors: For the underlying logit dose response model: Independent uniform distri-
butions (beta distribution with parameters 1 & 1) with   U[0:188;2:143] and  
U[0:206;0:615].
6. Potential non-missing probability function: Exponential function with estimated
parameters a = 1; b =  0:053, and c = 0:643.
Suppose we wish to estimate the underlying logit dose response curve using the D-optimality
criterion and also estimate the threshold dose (ED53) using the C-optimality criterion. As-
sume further that we are equally interested in both objectives. Accordingly, we set (1 = 2 =
0:5) . To generate the controlled optimal design, we rst select the standardized compound C-
and D-optimal design option (to account for dierent magnitude of the individual objective
functions) in Select the optimality criterion. In the next step   Specify the design
criteria, we enter 53 (for ED53) for Additional criteria other than the determinant, and 0.5,
0.5 for Corresponding compound optimal design weights (including the determinant). We ran
the Controlled Optimal Design 2.0 program and found two numerically controlled optimal
designs. They are:
 =
(
0 1 3
0:33 0:25 0:42
)
and  =
(
0 2 3
0:41 0:25 0:34
)
:
Rounding to the nearest integer, both designs are 100% ecient for estimating the threshold
dose ED53 and the dose response curve under the given constraints.Journal of Statistical Software 13
The design used by Kondo et al. (2004) has equal number of subjects at dosages 0, 1.5, and 3:
1 =
(
0 1:5 3
1=3 1=3 1=3
)
:
A direct calculation shows this design is 98% ecient for estimating the threshold dose ED53
and 97% ecient for estimating the dose response curve under the given constraints.
Like many other dose response studies, Kondo et al. (2004) was also interested in comparing
the response rates between the active dosages 1.5mg and 3mg to the placebo. The optimal
design for this purpose alone allocates equal number of subjects to the active dosages and p
2 times as many subjects to the placebo (Fleiss 1986; Zhu and Wong 2000b). This optimal
design is
2 =
(
0 1:5 3
0:414 0:293 0:293
)
and can be shown to have 96% eciency for estimating the threshold dose ED53 and 98%
eciency for estimating the dose response curve under the given constraints.
In summary, we have shown that the Controlled Optimal Design 2.0 program is able to
generate an optimal design that meets several practical constraints and the multiple goals
in the study. There are two controlled optimal designs  and  for the problem at hand.
Interestingly, both the equal allocation rule (1) adopted by Kondo et al. (2004) and the
best allocation scheme (2) for simultaneous treatment-placebo comparison purposes are also
highly ecient for the estimation of the threshold dose and the underlying dose response
curve. In our experience, such ndings are uncommon. In two other earlier dose response
trials that we worked on, the original designs were signicantly less ecient than the controlled
optimal designs. Our hope is that the Controlled Optimal Design 2.0 program will facilitate
and enable researchers to use more ecient and realistic designs in their work using minimal
resources and without sacricing statistical eciency.
5. Summary
In this paper, we introduced the Controlled Optimal Design 2.0 program for computing
multiple-objective Bayesian optimal designs in dose response studies satisfying several prac-
tical constraints on the dose range, dose levels, dose proportions, and potential missing trials
simultaneously. We used an innovative optimization code in our work and are encouraged
by the performance of the optimization method. Although the current program assumes an
underlying logit dose response model, the code can be readily extended to accommodate other
dose response models (Smith and Ridout 1998; Biedermann et al. 2006, 2007).
Our design website contains not only the Controlled Optimal Design 2.0 program but a
variety of codes for generating a variety of optimal designs for several popular models in
the health sciences. We hope that by providing our design programs on the website http:
//www.optimal-design.org/, we can help to bridge the gap between practice and theory,
and between the pharmaceutical industry and the optimal design research community. We
also hope to encourage researchers to work with web-based tools and use the internet as an
ecient venue for improving design practice and as an information exchange forum.14 Controlled Optimal Design Program for the Logit Dose Response Model
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